Analyst Update: Himax Technologies, Inc., Pacira Pharmaceuticals Inc, and RetailMeNot Inc

Analysts are weighing in on Himax Technologies, Inc. (ADR) (HIMX), Pacira Pharmaceuticals Inc (PCRX), and RetailMeNot Inc (SALE)

Sep 26, 2016 at 12:58 PM
facebook X logo linkedin


Analysts are weighing in on semiconductor stock Himax Technologies, Inc. (ADR) (NASDAQ:HIMX), biotech Pacira Pharmaceuticals Inc (NASDAQ:PCRX), and digital savings destination RetailMeNot Inc (NASDAQ:SALE). Here's a quick roundup of today's brokerage notes on HIMX, PCRX, and SALE.

  • HIMX has plunged 16.1% at $9 -- its worst percentage loss in four months -- after Nomura slashed its rating to "neutral" from "buy," and lowered its price target to $10.20 from $12. In a client note, the brokerage firm warned of weaker shipments of the company's major augmented reality (AR) device. Suffice it to say, Himax Technologies, Inc. has found a spot on the short-sale restricted (SSR) list, and is among the biggest decliners on the Nasdaq. Option bears should be in good shape, though. During the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), HIMX has racked up a put/call volume ratio of 1.31 -- higher than all other readings from the past year.
  • PCRX is off 3.7% at $35.51, following a $14 price-target cut to $60 at Jefferies. Year-to-date, the shares have now surrendered nearly 54% of their value. Given such terrible technicals, it would come as little surprise if Pacira Pharmaceuticals Inc was hit with additional bearish brokerage notes. After all, two-thirds of analysts rate the stock a "strong buy," with not a single "sell" opinion to be found. Plus, the consensus 12-month price target of $69.22 nearly doubles PCRX's present perch.
  • SALE is also resting on the SSR list, down 21.6% at $8.84. Pressuring the shares is a downgrade to "sell" from "hold" at Stifel. In fact, the gap lower has RetailMeNot Inc on the verge of closing its early August bull gap. Elsewhere, a bunch of former short sellers are likely kicking rocks this afternoon. During the last two reporting periods, short interest on SALE plummeted 36.6%, and just 2.2% of the stock's float is now shorted.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI